Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effectiveness of the SKILLS Program in the Management of Psychiatric Disorders

NCT06622993 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2024-11-14
Last updated
2026-06-12

Condition(s) studied

Psychiatric Disorders

Investigational drug(s) / intervention(s)

Psychotherapy

Psychotherapy: The experimental group will receive the SKILLS program, i.e. 10 group psychotherapy sessions.

Study summary

Epidemiological studies show that one person in eight suffers from at least one psychiatric disorder. Mental health is therefore a major public health issue, and care for these disorders must continue to be improved.

The management of mental disorders has long followed the traditional categorical approach of developing a treatment for a given disorder. However, researchers have recently pointed out the limits of this approach in the field of mental health. They highlight the large number of co-morbidities, the existence of aspecific disorders and the intra-diagnostic heterogeneity of patients. These factors have led them to develop a transdiagnostic approach, which focuses on the mechanisms common to the various disorders in order to treat them at the same time and thus reduce the cost of treatment.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Male or female ≥ 18 years of age * Have at least one diagnosis of a psychiatric disorder * Be able to carry out psychotherapy sessions * Have been on stable psychiatric medication for 30 days * Written informed consent obtained from the participant * Be affiliated to a social security scheme or equivalent Exclusion Criteria: * Cognitive deficits marked by a score above the 10th percentile for one or more tests in the assessment history. * Persons deprived of liberty by judicial or administrative decision; Persons under legal protection: guardianship or curatorship * Presence of a severe depressive episode * Be engaged in psychotherapeutic work elsewhere * Presence of a state of excessive deficit, making psychotherapy impossible * Presence of psychic decompensation (e.g. delusions) making psychotherapy impossible

Primary outcome measure(s)

  • Evolution in Symptom Checklist Scale (SCL 90) scores between randomization and Month 3 — At the randomisation and Month 3

Trial sites (1)

FacilityCityRegionStatus
Service psychiatrie Tours France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06622993 on ClinicalTrials.gov ↗ ← All trials in France